GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of ...

In the first month of 2025 on the ITF Masters Tour, Keith Porter won a pair of titles at an MT 400 event in Glasgow.

Pregnant women are now able to get the maternal RSV vaccine, Abrysvo, for free under the National Immunisation Program.

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

A vaccine designed to help protect babies from the respiratory syncytial virus (RSV) is now free during pregnancy. RSV is the ...

Pregnant women are now able to get the maternal RSV vaccine, Abrysvo, for free under the National Immunisation Program.

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.